Tonix Pharmaceuticals Enters Agreement With A Group Purchasing Organization To Provide Coverage For TONMYA To An Additional ~17M U.S. Commercial Lives From June 1

Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides access to approximately 17 million additional U.S. commercial lives (10% of the ~177 million commercial lives in the U.S.)

Total commercial coverage between two leading GPOs now approximately 52 million lives (29% of the total commercial lives in the U.S.)

TONMYA® is the first new fibromyalgia medicine for adults in over 15 years approved by the U.S. Food and Drug Administration (FDA)